Lexogen Enhances Next-Generation Sequencing Services with New GCLP Workflows

Introduction
In a significant stride towards elevating clinical research standards, Lexogen has announced the launch of newly designated next-generation sequencing (NGS) service workflows that comply with the principles laid out by the World Health Organization’s Good Clinical Laboratory Practice (GCLP). This expansion aims to meet the increasing demand for rigorous control processes in clinical trials, focusing on sample traceability, documentation, data integrity, and record retention.

The Importance of GCLP Compliance
In today's fast-evolving landscape of clinical research, adhering to GCLP ensures that laboratories uphold high standards in managing quality during sequences and data handling. Lexogen’s new offering incorporates a well-documented quality framework that covers all stages of the sequencing process, from the initial planning and sample receipt to library preparation, sequencing, post-analysis, technical reporting, data delivery, and archiving. This meticulous attention to detail underpins the laboratory's commitment to delivering reliable and auditable data, critical to the integrity of scientific research.

Innovative Technology and Quality Assurance
A standout feature of this service is the use of Lexogen's proprietary RNA sequencing and library preparation products, all manufactured in alignment with the company's ISO 13485 quality management system. This certification guarantees that production processes are not only controlled but also traceable, fostering consistency and reliability in results. Depending on project specifications, Lexogen is also able to employ other commercially available products and reagents, always ensuring that they meet the required standards for quality and traceability.

CEO Stéphane Barges emphasized the necessity for clinical research teams to partner with sequencing services that can provide robust and reliable data. He stated, “Our GCLP-compliant offering combines Lexogen's RNA sequencing expertise and proprietary technologies with the quality standards necessary for demanding clinical research.” This model supports researchers in obtaining insights from data that are both actionable and reliable, greatly enhancing the outcomes of clinical studies.

Customized Project Scope
Moreover, Lexogen's commitment to excellence is evident in their customized approach to project scope. Before commencing any project, specifics regarding sample types, input requirements, library preparation technologies, sequencing configurations, and bioinformatics analyses are comprehensively discussed and agreed upon in a structured study plan or statement of work. This proactive methodology ensures that all team members are aligned and expectations are clear, thereby strengthening project efficiency and success.

A Framework for Future Growth
Lexogen’s established GCLP-compliant workflows not only enhance current capabilities but also pave the way for future advancements in clinical and preclinical services. The company's internal assessments ensure compliance with these standards, prioritizing quality above all. As the biotechnology landscape continues to change, businesses like Lexogen are at the forefront, leading with innovative solutions that empower researchers to tackle complex biological inquiries.

Conclusion
For those seeking comprehensive, high-quality RNA sequencing services within a controlled framework, Lexogen's expansion into GCLP-compliant workflows is a game-changer. By focusing on reliability, integrity, and quality in sequencing processes, Lexogen positions itself as a pivotal player in advancing clinical research methodologies and outcomes. For more details about their services, visit Lexogen’s website.

About Lexogen
Lexogen is a leading biotechnology company specializing in RNA sequencing. The firm engineers and produces innovative solutions aimed at studying gene expression and transcriptomics. By providing robust products and services, Lexogen empowers advanced research and diagnostic applications, guaranteeing accuracy and consistency from the discovery phase through to routine testing.